Serum leptin and bone metabolism in HIV patients treated with highly active antiretroviral therapy

Quarterly Journal of Nuclear Medicine and Molecular Imaging

Volumn 53, Issue 3, 2009, Pages 290-301

  Madeddu, Giordano ^a   Spanu, A ^a   Chessa, F ^a   Calia, G M ^a   Lovigu, C ^a   Mannazzu, M ^a   Falchi, A ^a   Sanna, D ^a   Mura, M S ^a   Madeddu, Giuseppe ^a  

^a UNIVERSITY OF SASSARI   (Italy)

Author keywords

Antiretroviral therapy, highly active; Bone density; HIV; Leptin

Indexed keywords

1,25 DIHYDROXYERGOCALCIFEROL; ABACAVIR; ALKALINE PHOSPHATASE; DIDANOSINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; LEPTIN; LOPINAVIR; NELFINAVIR; NEVIRAPINE; OSTEOCALCIN; RITONAVIR; SAQUINAVIR; STAVUDINE; ZALCITABINE; ZIDOVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ADULT; ARTICLE; BLOOD LEVEL; BODY FAT; BODY MASS; BONE DENSITY; BONE METABOLISM; CONTROLLED STUDY; CROSS LINKING; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; OSTEOPENIA; OSTEOPOROSIS; PATHOPHYSIOLOGY; RADIOIMMUNOLOGY; URINE LEVEL; BLOOD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG EFFECT; PHOTON ABSORPTIOMETRY;

ABSORPTIOMETRY, PHOTON; ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BONE DENSITY; FEMALE; HIV INFECTIONS; HUMANS; LEPTIN; MALE;

EID: 70349572795     PISSN: 18244785     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (60)

1. Hickey MS, Considine RV, Israel RG, Mahar TL, McCamon MR, Tyndall GL et al. Leptin is related to body fat content in male distance runners. Am J Physiol 1996;34:E938-40.
2. Flier JS. Clinical review 94: what's in a name? In search of leptin's physiologic role. J Clin Endocrinol Metab 1998;83:1407-13.
3. Friedman JM, Halaas JL. Leptin and the regulation of body weight in mammals. Nature 1998;395:763-70.
4. Nicklas BJ, Katzel LI, Ryan AS, Dennis KE, Goldberg AP. Gender differences in the response of plasma leptin concentration to weight loss in obese older individuals. Obes Res 1997;5:62-8.
5. Mantzoros CR, Moschos S. Leptin: in search of role(s) in human physiology and pathophysiology. Clin Endocrinol 1998;49:551-67. (Pubitemid 28529751)
6. Havel PJ, Kasim-Karakas S, Bubuc GR, Mueller W, Phinney SD. Gender difference in plasma leptin concentration. Nat Med 1996;2:949-50. (Pubitemid 26306822)
7. Rosembaum M, Nicolson M, Hiersch J, Heymsfield SB, Gallager D, Chu F et al. Effects of gender, body composition and menopause of plasma concentration of leptin. J Clin Endocrinol Metab 1996;81:3424-7. (Pubitemid 26296228)
8. Isidori AM, Strollo F, Morè M, Caprio M, Aversa A, Moretti C et al. Leptin and aging: correlation with endocrine changes in male and female healthy adult population of different body weights. J Clin Endocrinol Metab 2000;85:1954-62.
9. Ducy P, Amling M, Takeda S, Priemel M, Schilling AF, Beil F et al. Leptin inhibits bone formation through a hypotalamic relay: a central control of bone mass. Cell 2000;100:197-207.
10. Karsenty G. Leptin controls bone formation through a hypothalamic relay. Recent Prog Horm Res 2001;56:401-15.
11. Prouteau S, Benhamou L, Courteix D. Relationship between serum leptin and bone markers during stable weight, weight reduction and weight regain in male and female judoist. Eur J Endocrinol 2006;154:389-95.
12. Woods AJ, Stock M. Leptin activation in hypothalamus. Nature 1996;381:745.
13. Auwerx J, Staels B. Leptin. Lancet 1998;351:737-42.
14. Goulding A, Taylor RW. Plasma leptin values in relation to bone mass and density and to dynamic biochemical markers of bone resorption and formation in postmenopausal women. Calcif Tissue Int 1998;63:456-8. (Pubitemid 28531792)
15. Yamauchi M, Sugimoto T, Yamaguchi T, Nakaoda D, Kanzawa M, Yano S et al. Plasma leptin concentrations are associated with bone mineral density and the presence of vertebral fractures in postmenopausal women. Clin Endocrinol 2001;55:341-7. (Pubitemid 32823044)
16. Zhong N, Wu XP, Xu ZR, Wang AH, Luo XH, Cao XZ et al. Relationship of serum leptin with age, body weight, body mass index, and bone mineral density in healthy mainland Chinese women. Clin Chim Acta 2005;351:161-8. (Pubitemid 39563571)
17. Martini G, Valenti R, Giovani S, Franci B, Campagna S, Nuti R. Influence of insulin-like growth factor-1 and leptin on bone mass in healthy postmenopausal women. Bone 2001;28:113-7. (Pubitemid 32114090)
18. Roux C, Arabi A, Porcher R, Garnero P. Serum leptin as a determinant of bone resorption in healthy postmenopausal women. Bone 2003;33:847-52. (Pubitemid 37393496)
19. Sato M, Takeda N, Sarui H, Takami R, Takami K, Hayashi M et al. Association between serum leptin concentrations and bone mineral density, and biochemical markers of bone turnover in adult men. J Clin Endocrinol Metab 2001;86:5273-6.
20. Morberg CM, Tetens I, Black E, Toubro S, Soerensen TI, Pedersen O et al. Leptin and bone mineral density: a cross-sectional study in obese and nonobese men. J Clin Endocrinol Metab 2003;88:5795-800.
21. Kontogianni MD, Dafni UG, Routsia JG, Skopouli FN. Blood leptin and adiponectin as possible mediators of the relation between fat mass and BMD in perimenopausal women. J Bone Miner Res 2004;19:546-51.
22. Cozzolino M, Vidal M, Arcidiacono MV, Tebas P, Yarasheski KE, Dusso AS. HIV protease inhibitor impair vitamin D bioactivation to 1,25-dihydroxyvitamin D. AIDS 2003;17:513-20.
23. Madeddu G, Spanu A, Solinas P, Calia GM, Lovigu C, Chessa F et al. Bone mass loss and vitamin D metabolism impairment in HIV patients receiving highly active antiretroviral therapy. Q J Nucl Med Mol Imaging 2004;48:39-48. (Pubitemid 39069663)
24. García Aparicio AM, Muñoz Fernández S, Gonzáles J, Arribas JR, Peña JM, Vázquez JJ et al. Abnormalities in the bone mineral metabolism in HIV-infected patients. Clin Rheumatol 2006;25:537-9.
25. Grunfeld C, Pang M, Shigenega JK, Jensen P, Lallone R, Friedman J et al. Serum leptin levels in the acquired immunodeficinecy syndrome. J Clin Endocrinol Metab 1996;81:4342-6.
26. Yarasheski KE, Zachwieja JJ, Horgan MM, Powderly WG, Santiago JV, Landt M. Serum leptin concentrations in human immunodeficiency virus-infected men with low adiposity. Metabolism 1997;46:303-5.
27. Mantzoros CS, Moschos S, Avramopoulos I, Kaklamani V, Liolios A, Doulgerakis DE et al. Leptin concentrations in relation to BMI and the TNFa system in humans. J Clin Endocrinol Metab 1997;82:3408-13.
28. Zumbach MS, Boehma MWJ, Wahl P, Stremmel W, Ziegler R, Nawroth PP. Tumor necrosis factor increases serum leptin levels in humans. J Clin Endocrinol Metab 1997;82:4080-2.
29. Janik JE, Cutri BD, Considine RV, Rager HC, Powers GC, Alvord WG et al. Interleukin la increases serum leptin concentrations in humans. J Clin Endocrinol Metab 1997;82:3084-6.
30. Sarraf P, Frederich R, Turner E, Ma G, Jaskowiak NT, Rivet DJ 3d et al. Multiple cytokines and acute inflammation raise mouse leptin levels: potential role in inflammatory anorexia. J Exp Med 1997;85:171-5.
31. Aukrust P, Liabakk NB, Müller F, Lien E, Espevik T, Frøland SS. Serum levels of tumor necrosis factor (TNF) ?and soluble TNF receptors in human immunodeficiency virus type 1 infection-correlations to clinical, immunologic, and virologic parameters. J Infect Dis 1994;169:420-4.
32. Serrano S, Marinoso ML, Soriano JC, Rubies-Prat J, Aubia J, Coll J et al. Bone remodeling in human immunodeficiency virus-1 infected patients. A histomorphometric study. Bone 1995;16:185-91.
33. Alsina M, Guise TA, Roodman GD. Cytokine regulation of bone cell differentiation. Vitam Horm 1996;52:63-98.
34. Nacher M, Serrano S, Gonzàles A, Hernàndez A, Mariñoso ML, Vilella R et al. Osteoblast in HIV-infected patients: HIV-1 infection and cell function. AIDS 2001;15:2239-43.
35. Palella FJ, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998;338:853-60.
36. Carr A, Samaras K, Burton S, Law M, Freund J, Chisholm DJ et al. A syndrome of peripheral lipodystrophy, hyperlipidemia, and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998;12:F51-2.
37. Nolan D, Upton R, McKinnon E, John M, James I, Adler B et al. Stable or increasing bone mineral loss in HIV-infected patients treated with nelfinavir or indinavir. AIDS 2001;15:1275-80.
38. Rietschel P, Corcoran C, Stanley T, Basgoz N, Klinbansky A, Grinspoon S. Prevalence of hypogonadism among men with weight loss related to human immunodeficiency virus infection who were receiving highly active antiretroviral therapy. Clin Infect Dis 2000;31:1240-4.
39. Grappin M, Piroth L, Verges B, Sgro C, Mack G, Buisson M et al. Increased prevalence of subclinical hypothyroidism in HIV patients treated with highly active antiretroviral therapy. AIDS 2000;26:1070-2.
40. Calza L, Manfredi R, Chiodo F. Subclinical hypothyroidism in HIV-infected patients receiving highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2002;31:361-3.
41. Madeddu G, Spanu A, Chessa F, Calia GM, Lovigu C, Solinas P et al. Thyroid function in human immunodeficiency virus patients treated with highly active antiretroviral therapy (HAART): a longitudinal study. Clin Endocrinol 2006;4:375-83.
42. Tebas P, Powderly WG, Claxton S, Marin D, Tantisiriwar W, Teitelbaum SL et al. Accelerated bone mineral loss in HIV-infected patients potent antiretroviral therapy. AIDS 2000;14:F63-7.
43. Moore A, Vashisht A, Sabin CA, Mocroft A, Madge S, Phillips AN et al. Reduced bone density in HIV-positive individuals. AIDS 2001;15:1731-3.
44. Brown TT, Qaqish RB. Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review. AIDS 2006;20:2165-74.
45. Huang JS, Rietschel P, Hadigan CM, Rosenthal DL, Grinspoon S. Increased abdominal visceral fat is associated with reduced bone density in HIV-infected men with lipodystrophy. AIDS 2001;15:975-82. (Pubitemid 32476664)
46. Mora S, Sala N, Bricalli D, Zuin G, Chiumello G, Vigano A. Bone mineral loss through increased bone turnover in HIV-infected children treated with highly active antiretroviral therapy. AIDS 2001;15:1823-9.
47. Aukrust P, Huag CJ, Ueland T, Lien E, Müller F, Espevik T et al. Decreased bone formative and enhanced resorptive markers in human immunodeficiency virus infection: indication of normalization of the bone-remodelling process during highly active anti-retroviral therapy. J Clin Endocrinol Metab 1999;84:145-50. (Pubitemid 29036693)
48. Kotier DP, Wang J, Pierson RN. Body composition studies in patients with acquired immunodeficiency syndrome. Am J Clin Nutr 1985;42:1255-65. (Pubitemid 16166024)
49. Yilmazi M, Keles I, Aydin G, Orkun S, Bayram M, Sevinc FC et al. Plasma leptin concrentrations in postmenopausal women with osteoporosis. Endocr Res 2005;31:133-8. (Pubitemid 41760429)
50. Iwamoto I, Douchi T, Kosha S, Murakami M, Fujino T, Nagata Y. Relationships between serum leptin level and regional bone mineral density, bone metabolic markers in healthy women. Acta Obstet Gynecol Scand 2000;79:1060-4.
51. Haug CJ, Aukrust P, Haug E, Morkrid L, Müller F, Frøland SS. Severe deficiency of 1,25-dihidroxivitamin D3 in human immunodeficiency virus infection: association with immunological hyperactivity and only minor changes in calcium homeostasis. J Clin Endocrinol Metab 1998;83:3832-8. (Pubitemid 28513558)
52. Mynarcik DC, Combs T, McNurlan MA, Scherer PE, Komaroff E, Gelato MC. Adiponectin and leptin levels in HIV-infected subjects with insulin resistance and body fat redistribution. J Acquir Immune Defic Syndr 2002;31:514-20.
53. Kosmiski L, Kuritzekes D, Lichtenstein K, Eckel R. Adipocyte-derived hormone levels in HIV lipodystrophy. Antivir Ther 2003;8:9-15.
54. Carr A, Samaras K, Thorisdottir A, Kaufmann GR, Chisholm DJ, Cooper DA. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet 1999,
55. Savès M, Raffi F, Capeau J, Rozembaum W, Raganud JM, Perronne C et al. Factors related to lipodystrophy and metabolic alterations in patients with human immunodeficiency virus infection receiving highly active antiretroviral therapy. Clin Infect Dis 200;234:1396-405.
56. + children during highly active antiretroviral therapy. Clin Endocrinol 2002;57:643-6.
57. Papaevangelou V, Papassotiriou I, Vounatsou M, Chrousos G, Theodoridou M. Changes in leptin serum levels in HIV-infected children receiving highly active antiretroviral therapy. Scand J Clin Lab Invest 2007;67:291-6.
58. Lord GM, Matarese G, Howard JK, Baker RJ, Bloom SR, Lechler RI. Leptin modulates the T-cell immune response and reverses starvation-induced immunosuppression. Nature 1998;394:897-901.
59. Howard JK, Lord GM, Matarese G, Vendetti S, Ghatei SM, Ritter M et al. Leptin protects mice from starvation-induced lymphoid atrophy and increases thymic cellularity in ob/ob mice. J Clin Invest 1999;104:1051-9.
60. Haynes BF, Markert ML, Sempowski GD, Patel DD, Hale LP. The role of the thymus in immune reconstitution in aging, bone marrow transplantation, and HIV-1 infection. Annu Rev Immunol 2000;18:529-60.